TDC
ALPN

Thompson Davis & Co’s Alpine Immune Sciences Inc ALPN Stock Holding History

Thompson Davis & Co’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-250
Closed -$3K – 1196
2017
Q1 		$3K Buy
+250
New +$2.53K ﹤0.01% 1019

Other funds holding ALPN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Thompson Davis & Co's ALPN Position: Q2 2017 in Review

Thompson Davis & Co sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2017, closing a stake of 250 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in ALPN in Q1 2017 and held it in 1 quarter. The position peaked at $3K in Q1 2017. 26 funds tracked by Wall St. Rank hold ALPN as of Q2 2017.

  • Thompson Davis & Co reported no remaining Alpine Immune Sciences Inc position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 250 Alpine Immune Sciences Inc shares in Q2 2017, an estimated $3K.
  • Thompson Davis & Co first reported a position in Alpine Immune Sciences Inc in Q1 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Alpine Immune Sciences Inc position peaked at $3K in Q1 2017.
  • 26 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.